Fosun Pharma Launches AI-Driven PharmAID Platform for Enhanced Drug Development
Fosun Pharma has introduced its self-developed PharmAID decision intelligence platform, integrating advanced AI technologies to boost drug R&D efficiency, announced in a press release. The platform is designed to enhance decision-making accuracy and accelerate the transformation of R&D achievements.
The PharmAID platform incorporates global leading large model technologies and connects with Deepseek R1, aiming to improve drug commercial value-assisted decision-making capabilities. It enhances drug R&D efficiency by integrating various predictive and analytical tools, such as point prediction, conformational prediction, and toxicology optimization.
Additionally, the platform offers AI translation and medical writing features, significantly improving information retrieval and writing efficiency. Fosun Pharma's initiative marks a significant step in the AI transformation of the pharmaceutical industry, aiming to lead innovation and transformation with its first self-developed AI decision intelligence platform.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 31 Patient Sues Allegheny Health Network and Highmark Over Abridge AI Recordings Oct 31 OpenAI Releases GPT-Rosalind-6 for Approved Biology Researchers Oct 30 Surveys Find Widespread AI Chatbot Use Among Teens and Tweens Oct 30 Widow Sues OpenAI and Luka Over Husband's Suicide Oct 29 Canadian Privacy Regulators Call for AI Rules in Health CareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
ALLOX Raises $10.5 Million for AI Drug Discovery Platform
Apodex Offers Free AI Drug Research Services
Pathos AI Raises $237 Million at $3 Billion Valuation
Inovia Bio Launches Falcon for Drug Development Workflows
Quotient Sciences and Acesion Apply AI to Atrial Fibrillation Drugs
Daily AI Brief: the AI news that matters, in your inbox.